It has been reported that CDK4 knockdown impedes the colony formation and cell proliferation of glioma [36], and that PBK and SLC2A3 could be a potential prognostic factor and therapeutic target for GBM treatment [37,38]. This evidence concerns the gene CDK4 and glioma.